Molecular Technology Poised to Change Point-of-Care Dx Setting | GenomeWeb

NEW YORK (GenomeWeb) – After a years-long tease, molecular diagnostic technologies are starting to enter the point-of-care space, prompting expectations that it could drastically change how testing is done in a broad range of clinical settings. 

In less than two years, three firms have launched or unveiled molecular platforms targeting the point-of-care market in a first wave of such instruments to hit the space. In January 2014, Alere launched its Alere i system in parts of Europe, followed by the launch of its Alere q platform in July 2014. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.